{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:35:23Z","timestamp":1791257723950,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,3,12]],"date-time":"2012-03-12T00:00:00Z","timestamp":1331510400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>One of the most important risk factors for stroke is hypertension. A number of studies have attempted to identify the most effective anti-hypertensive therapeutic group for stroke prevention. Using an epidemiologic approach we aimed to find correlations based on Hungarian data on stroke-mortality and on prescription routine of anti-hypertensive therapeutics in three different counties, showing significant difference in stroke mortality.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We have used the official yearly reports on stroke-mortality for the period 2003-2008. Based on the significant differences in the change in mortality due to stroke three counties were selected: Baranya, Bekes and Hajdu-Bihar. The usage of antihypertensive therapeutic groups was analyzed. The correlation of stroke mortality difference and different antihypertensive treatment habits was analyzed by using normality test, time series analyses, correlation coefficient, paired samples test, one sample test and chi-square test.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>For the year 2003 stroke-mortality standardized with the county population number was highest in county Bekes, followed by county Baranya and county Hajdu-Bihar. For each year stroke mortality has shown significant (p &lt; 0.0001) difference between the three counties and the ranking\/order of the counties has been preserved over time. During the period of our study, an increase in the number of days of treatment was observed for most of the anti-hypertensive drugs listed. We have observed that the increased use of high-ceiling diuretics resulted in a mortality advantage, and the reduction in use of calcium channel blockers with direct cardiac effect had negative consequences.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The authors acknowledge that by limiting the study to three counties the findings cannot be generalized to the whole Hungarian population. Two trends can still be identified:<\/jats:p>\n            <jats:p>i) increased number of days of treatment (and therefore the probable use) of high-ceiling diuretics is associated with reduction in mortality due to stroke and its immediate complications; ii) reduction in the use of non-dihidropiridin CCBs does not seem justified, as their use appears to be advantageous in stroke prevention. Authors put emphasis on the importance of the adherence of the patients to the preventive therapies. Health care professionals could provide an important added value to the life long preventive therapies by improving the compliance of their patients, giving personalized care and advice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2261-12-15","type":"journal-article","created":{"date-parts":[[2012,3,12]],"date-time":"2012-03-12T17:14:29Z","timestamp":1331572469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Correlations between prescription of anti-hypertensive medication and mortality due to stroke"],"prefix":"10.1186","volume":"12","author":[{"given":"Renata","family":"Papp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Csaszar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edit","family":"Paulik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandor","family":"Balogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,12]]},"reference":[{"key":"430_CR1","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/1471-2458-10-422","volume":"10","author":"S Balogh","year":"2010","unstructured":"Balogh S, Papp R, Jozan P, Csaszar A: Continued improvement of cardiovascular mortality in Hungary-impact of increased cardio-metabolic prescriptions. BMC Publ Health. 2010, 10: 422-10.1186\/1471-2458-10-422.","journal-title":"BMC Publ Health"},{"issue":"9349","key":"430_CR2","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington S, Clarke R, Qizilbash N, Peto R, Collins R: Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002, 360 (9349): 1903-1913.","journal-title":"Lancet"},{"issue":"6","key":"430_CR3","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1097\/HJH.0b013e3280dce59e","volume":"25","author":"AP Kengne","year":"2007","unstructured":"Asia Pacific Cohort Studies Collaboration, Kengne AP, Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Gu DF, Suh I, Woodward M: Systolic blood pressure, diabetes and the risk of cardiovascular diseases in the Asia-Pacific region. J Hypertens. 2007, 25 (6): 1205-1213.","journal-title":"J Hypertens"},{"issue":"6","key":"430_CR4","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1161\/01.STR.0000223048.70103.F1","volume":"37","author":"LB Goldstein","year":"2006","unstructured":"Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, Degraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco R, American Heart Association\/American Stroke Association Stroke Council; Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; Quality of Care and Outcomes Research Interdisciplinary Working Group; American Academy of Neurology: Primary prevention of ischemic stroke: a guideline from the American Heart Association\/American Stroke Association Stroke Council. Stroke. 2006, 37 (6): 1583-1633.","journal-title":"Stroke"},{"issue":"9395","key":"430_CR5","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","volume":"362","author":"F Turnbull","year":"2003","unstructured":"Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003, 362 (9395): 1527-1535.","journal-title":"Lancet"},{"key":"430_CR6","doi-asserted-by":"publisher","first-page":"b1665","DOI":"10.1136\/bmj.b1665","volume":"338","author":"MR Law","year":"2009","unstructured":"Law MR, Morris JK, Wald NJ: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009, 338: b1665-10.1136\/bmj.b1665.","journal-title":"BMJ"},{"issue":"2","key":"430_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1161\/01.HYP.0000174591.42889.a2","volume":"46","author":"P Verdecchia","year":"2005","unstructured":"Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L, Staessen JA, Porcellati C: Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005, 46 (2): 386-392. 10.1161\/01.HYP.0000174591.42889.a2.","journal-title":"Hypertension"},{"key":"430_CR8","unstructured":"Hungarian Central Statistical Office. [http:\/\/www.ksh.hu]"},{"key":"430_CR9","unstructured":"National Health Insurance Fund. [http:\/\/www.oep.hu]"},{"issue":"2","key":"430_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1161\/01.HYP.0000231939.40959.60","volume":"48","author":"H Zhang","year":"2006","unstructured":"Zhang H, Thijs L, Staessen JA: Blood pressure lowering for primary and secondary prevention of stroke. Hypertension. 2006, 48 (2): 187-195. 10.1161\/01.HYP.0000231939.40959.60.","journal-title":"Hypertension"},{"issue":"9246","key":"430_CR11","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(00)03306-7","volume":"356","author":"M Pahor","year":"2000","unstructured":"Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, Furberg CD: Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet. 2000, 356 (9246): 1949-1954. 10.1016\/S0140-6736(00)03306-7.","journal-title":"Lancet"},{"issue":"9","key":"430_CR12","first-page":"817","volume":"17","author":"F Angeli","year":"2004","unstructured":"Angeli F, Verdecchia P, Reboldi GP, Gattobigio R, Bentivoglio M, Staessen JA, Porcellati C: Calcium channel blockade to prevent stroke in hypertension: ameta-analysis of 13 studies with 103,793 subjects. Am J Hypertens. 2004, 17 (9): 817-822.","journal-title":"Am J Hypertens"},{"issue":"11","key":"430_CR13","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1586\/erc.09.102","volume":"7","author":"RM Cooper-DeHoff","year":"2009","unstructured":"Cooper-DeHoff RM, Handberg EM, Mancia G, Zhou Q, Champion A, Legler UF, Pepine CJ: INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study. Expert Rev Cardiovasc Ther. 2009, 7 (11): 1329-1340. 10.1586\/erc.09.102.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"430_CR14","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1097\/00004872-199816110-00014","volume":"16","author":"A Zanchetti","year":"1998","unstructured":"Zanchetti A, Agabiti RE, Dal P, Leonetti G, Magnani B, Pessina A, The VHAS Study Group: The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotis intima-media thickness. J Hypertens. 1998, 16: 1667-1676. 10.1097\/00004872-199816110-00014.","journal-title":"J Hypertens"},{"issue":"9227","key":"430_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","volume":"356","author":"L Hansson","year":"2000","unstructured":"Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahl\u00f6f B, Karlberg BE: Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000, 356 (9227): 359-365. 10.1016\/S0140-6736(00)02526-5.","journal-title":"Lancet"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2261-12-15.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2261-12-15\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2261-12-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2261-12-15.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T18:42:22Z","timestamp":1630521742000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/1471-2261-12-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,12]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["430"],"URL":"https:\/\/doi.org\/10.1186\/1471-2261-12-15","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,12]]},"assertion":[{"value":"2 August 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"15"}}